Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

Kathleen Beusterien,1 Martine C Maculaitis,2 Bernadette Hallissey,1 Michael M Gaschler,2 Mary Lou Smith,3 Ernest H Law4 1Kantar, Health Division, Horsham, PA, USA; 2Kantar, Health Division, New York, NY, USA; 3Research Advocacy Network, Plano, TX, USA; 4Pfizer Oncology, Pfizer Inc, New York, NY, USA...

Full description

Bibliographic Details
Main Authors: Beusterien K, Maculaitis MC, Hallissey B, Gaschler MM, Smith ML, Law EH
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:Patient Preference and Adherence
Subjects:
cyclin-dependent kinase 4/6 inhibitors
endocrine therapy
treatment preferences
stage ii/iii breast cancer
Online Access:https://www.dovepress.com/patient-oncologist-and-payer-preferences-for-adjuvant-endocrine-therap-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/patient-oncologist-and-payer-preferences-for-adjuvant-endocrine-therap-peer-reviewed-article-PPA

Similar Items